Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophagogastric Junction
- Gastric Adenocarcinoma
- Gastric Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Background: An estimated 24,590 cases of gastric adenocarcinoma are diagnosed annually in the U.S. The peritoneal surface is a site of metastasis found often at time of diagnosis and is a common (40%) site of recurrence. Laparoscopy with peritoneal lavage and cytopathologic analysis is a staging mod...
Background: An estimated 24,590 cases of gastric adenocarcinoma are diagnosed annually in the U.S. The peritoneal surface is a site of metastasis found often at time of diagnosis and is a common (40%) site of recurrence. Laparoscopy with peritoneal lavage and cytopathologic analysis is a staging modality that can identify a subset of patients with microscopic peritoneal metastasis prior to consideration for definitive surgical therapy Intraperitoneal chemotherapy has been employed in advanced gastric cancers and as an adjuvant with an associated improvement in survival in systematic reviews Objectives: - Determine the overall survival in patients with cytology-positive gastric cancer treated with HIPEC and gastrectomy Eligibility: Histologically confirmed adenocarcinoma of the stomach Cytopathologic evidence of peritoneal carcinomatosis Medically fit for systemic chemotherapy, HIPEC and gastrectomy Design: - Single arm, phase II study of HIPEC and gastrectomy
Tracking Information
- NCT #
- NCT03092518
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Jeremy L Davis, M.D. National Cancer Institute (NCI)
Get Well Soon